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Heart failure and arrhythmia of all kinds are natural bed fellows, but within cohorts of 
patients with systolic heart failure there lurks a group of individuals whose ventricular 
dysfunction is the result and not the cause of their cardiac rhythm disturbance. The first case 
reports of tachycardia induced cardiomyopathy (TIC) appeared in the early years of the 20th 
century, but it was only in 1962 that Whipple and colleagues described the first experimental 
model of pacing induced heart failure (1). This standard model has been used in numerous 
large animal experiments to create a phenotype in which the severity of pacing induced left 
ventricular dysfunction relates to the rate, duration and site of pacing with chronic ventricular 
pacing being the most detrimental (2,3).  
 
In man, TIC is described in various settings including atrial fibrillation (AF), incessant 
supraventricular tachycardia, frequent ventricular ectopy and ventricular tachycardia (2,3). 
Perhaps the purest model for TIC is incessant (i.e. present at least 90 % of the time) atrial 
tachycardia in which left ventricular dysfunction occurs in up to 10 % of individuals (4). 
Successful treatment of the tachycardia in this setting improves left ventricular function in the 
overwhelming majority of cases. A more common TIC is that associated with chronic atrial 
fibrillation (AF) with poor rate control (5). Caveats to this observation are that the estimation 
of ejection fraction during rapid AF is technically challenging and studies have also 
suggested that the irregularity of AF may itself be detrimental to LV function independent of 
the ventricular rate response (3,5,6). Another relatively common scenario is that of frequent 
premature ventricular complexes (PVC) in which TIC is related to the frequency of PVCs as 
well as their absolute burden, ectopic coupling interval, QRS duration and site of origin 
(2,3,7). 
 
In this edition of the journal, Müller and colleagues report a very thorough analysis of 
endomyocardial biopsies taken from patients with a presumptive diagnosis of TIC (8). In a 
retrospective series of 189 patients with new onset heart failure, they identified 19 individuals 
with TIC defined by an admission heart rate >100 bpm, rhythm other than sinus, recovery of 
LV ejection fraction after restoration of sinus rhythm or rate control, and exclusion of other 
causes of heart failure. The remainder of the study population were classified as either dilated 
cardiomyopathy (DCM) or inflammatory cardiomyopathy (ICM) in accordance with 
published histopathological criteria (9). Compared to healthy myocardial samples, biopsies 
taken from patients with TIC showed a focal loss of myofibrils, abnormally lobulated nuclear 
membranes and marked variation in size and architecture of mitochondria. Mitochondria 
were also abnormally located near intercalated discs and RNA expression analysis revealed a 
distinct pattern characterized by increased expression of mitochondrial pyruvate carrier 1 
(MPC1). Compared to DCM and ICM, myocardial samples from patients with TIC had 
greater expression of MHC class II molecules, infiltration of CD68+ macrophages, absent or 
low levels of CD3+ T-cells and less myocardial fibrosis. While the cause of these changes–in 
particular, the macrophage infiltration–is unknown, the authors conclude that TIC is 
characterized by histological and biochemical features that differ significantly from other 
cardiomyopathies.  
 
These intriguing findings add to an existing body of evidence derived mostly from animal 
studies. Other than the defining changes in LV cavity dimensions and function, numerous 
changes at cellular level are described including cellular elongation, myofibrillar disruption, 
cardiomyocyte apoptosis and myocardial fibrosis (2,3). Changes in the structure, distribution 
and function of the coronary microvasculature are also described and have led to the 
suggestion that myocardial ischemia is a contributor to TIC. Reported biochemical changes in 
pacing induced cardiomyopathy include reduced myocardial energy stores (creatine, 
phosphocreatine, adenosine triphosphate and glycogen), increased Kreb’s cycle activity, and 
decreased activity of the sodium-potassium adenosine triphosphatase (Na-K-ATPase) pump 
consistent with mitochondrial injury. Increased levels of oxidative stress accompany myocyte 
apoptosis in animal models of TIC and reduction of oxidative stress (e.g. with antioxidant 
vitamins) attenuates cardiac dysfunction. Other reported findings include raised endothelin-1 
(ET-1) levels and downregulation of beta-adrenergic receptors and calcium cycling. 
 
There are some obvious limitations to the study by Muller and colleagues. Foremost is the 
retrospective design which introduces the inevitable risk of selection bias. The second is the 
reliance on the admission heart rate for the definition of TIC. This will have been dependent 
on many factors, not least the severity of heart failure and the intensity of drug therapy on 
admission. Resting heart is also an unreliable measure of tachycardia burden in patients with 
AF in whom heart rate can rise precipitously with mild physical exertion. Finally, some of the 
observed changes reported are not unique to TIC, but are seen in other forms chronic heart 
failure where they reflect the downstream effects of elevated filling pressures and decreased 
cardiac output rather than the tachycardia itself. Nevertheless, this is the first study in humans 
to characterize the cellular phenotype of TIC in vivo. One of the major issues in TIC is the 
fact that it is a diagnosis of exclusion with no single confirmatory test. If the histological 
changes identified in this study can be replicated in prospective studies, then endomyocardial 
biopsy could have a role in selected cases when the diagnosis of TIC is in doubt. A second 
important message from this study is that some of the observed histological changes are 
probably irreversible, emphasizing the need for a high level of clinical suspicion for TIC and 
prompt treatment of the causative arrhythmia by pharmacological or other means. In other 
words, diagnosis of the cause of left ventricular dysfunction matters. 
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